![EV wave still on horizon, but smaller than prior tsunami](https://i-invdn-com.investing.com/news/LYNXNPEE8G0G4_S.jpg)
Please try another search
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for glioblastoma and hematological or solid tumors. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
Name | Age | Since | Title |
---|---|---|---|
Christian Jacques | 68 | 2018 | Member of Clinical Advisory Board |
Jennifer Jackson | 71 | 2018 | Independent Director |
Brian M. Stuglik | 65 | 2018 | Independent Director |
Per Anders Göte Samuelsson | 63 | 2012 | Independent Director |
Axel Gaston Glasmacher | 64 | - | Member of Clinical Advisory Board |
Jarl Ulf Jungnelius | 73 | 2011 | Independent Director |
Paul G. Richardson | - | - | Member of Clinical Advisory Board |
Per Wold-Olsen | 77 | 2018 | Independent Chairman of the Board |
Lori Anne Kunkel | 66 | - | Member of Clinical Advisory Board |
Cecilia Daun Wennborg | 61 | 2017 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review